Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics to Patients

September 13, 2021

Octarine Bio, the synthetic biology drug development company that produces psilocybin from sugar using fermentation, partners with clinical research organisation Clerkenwell Health to deliver clinical trials.
– Europe’s commercial psychedelic healthcare ecosystem is growing, building on a strong heritage of academic and civil society support
– A partnership between these two innovative startups leads the way for advancing patient access to psychedelic medicines in Europe
– Octarine Bio uses yeast fermentation to produce psilocybin from sugar which comes with many benefits such as low cost, sustainability, and supply chain stability
– Clerkenwell Health is well positioned to accelerate the psychedelic sector by offering …

Read the source article at sg.finance.yahoo.com
2021-09-08 13:05:00

Share This Story!